BioSpace News Archive

Accuryn Medical, innovator of the Accuryn Monitoring System, a device designed to monitor the kidney, reduce the risks associated with catheter-associated urinary tract infections and streamline nurse workflow, announced a significant leadership transition.

Medline, a market-leading manufacturer and supplier of medical supplies and solutions, is pleased to announce that it is now a direct distributor for Epredia, a member of PHC Group.

According to Nova One Advisor, the global biochip market size was estimated at USD 12.28 billion in 2023 and is projected to hit around USD 40.49 billion by 2033, growing at a CAGR of 12.67% during the forecast period from 2024 to 2033.

The RNAi therapeutics market size reached a value of USD 1.11 billion by 2023 is expected to surge USD 4.28 billion by 2033, projections indicate an impressive CAGR of 14.9% over the forecast period 2023 – 2033, a study by Towards Healthcare.

According to the latest Research by Nova One Advisor, the global biologics market size was exhibited at USD 511.04 billion in 2024 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2024 to 2033.

Koning Health, a leader in innovative medical imaging technology, is proud to announce the first installation of its groundbreaking Koning Vera Breast CT system in the New York City metropolitan area at Community Radiology NY on Canal Street.

Global Biopharmaceutical Fermentation Market is valued at US$ 10.17 Bn in 2023, and it is expected to reach US$ 16.03 Bn by 2031, with a CAGR of 6.11% during the forecast period of 2024-2031.

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company’s first quarter financial results.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.

SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.